1. Home
  2. VSTD vs CMND Comparison

VSTD vs CMND Comparison

Compare VSTD & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTD

Vestand Inc.

N/A

Current Price

$0.23

Market Cap

6.3M

ML Signal

N/A

Logo Clearmind Medicine Inc.

CMND

Clearmind Medicine Inc.

HOLD

Current Price

$2.12

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTD
CMND
Founded
2016
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
5.3M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
VSTD
CMND
Price
$0.23
$2.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
659.1K
429.1K
Earning Date
03-27-2026
01-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,902,861.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.39
N/A
52 Week Low
$0.20
$2.12
52 Week High
$5.63
$70.00

Technical Indicators

Market Signals
Indicator
VSTD
CMND
Relative Strength Index (RSI) N/A 68.83
Support Level N/A $2.40
Resistance Level N/A $2.88
Average True Range (ATR) 0.00 0.21
MACD 0.00 0.14
Stochastic Oscillator 0.00 67.65

Price Performance

Historical Comparison
VSTD
CMND

About VSTD Vestand Inc.

Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Share on Social Networks: